SavedAdd your journal

Journals / Atlas Journal of Medicine / 2026 / Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı

Is Surgery Still the Main Treatment for Breast Cancer?

Meme kanserinde ana tedavi hala cerrahi mi?

Muhammed Özdemir(Tc.sağlık bakanlığı sbü gaziosmanpaşa eğitim ve araştırma hastanesi)0000-0001-5377-6425
Pages
1–6
Publication Date
2026-05-08
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With the efforts to reduce the size of surgery day by day, the number of early-stage breast cancer patients increasing with screening programs, and minimally invasive techniques being discussed today, the standard treatment in current guidelines for patients in all treatable stages is still surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is the most frequently diagnosed cancer in the world.
📊
Key Findings & Data:Since its first diagnosis, strategies have been tried to be developed to reduce mortality and morbidity.
💡
Conclusion & Impact:With the efforts to reduce the size of surgery day by day, the number of early-stage breast cancer patients increasing with screening programs, and minimally invasive techniques being discussed today, the standard treatment in current guidelines for patients in all treatable stages is still surgery.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Meme kanseri tedavisi · mastektomi · meme koruyucu cerrahi

Abstract

Breast cancer is the most frequently diagnosed cancer in the world. Since its first diagnosis, strategies have been tried to be developed to reduce mortality and morbidity. Learning about the biological behavior of breast cancer, developments in science and technology, and the inadequacy of radical surgery alone in improving prognosis have led to the need to develop different treatment models in breast cancer treatment together with surgery. With the understanding that breast cancer is a systemic disease, it has been seen that the best results can be achieved with a multidisciplinary approach. With the efforts to reduce the size of surgery day by day, the number of early-stage breast cancer patients increasing with screening programs, and minimally invasive techniques being discussed today, the standard treatment in current guidelines for patients in all treatable stages is still surgery.

Özet

Meme kanseri dünyada en sık tanı konulan kanserdir. Tanımlandığı ilk günden bugüne mortalite ve morbiditeyi azaltacak stratejiler geliştirilmeye çalışılmıştır. Meme kanserinin biyolojik davranış biçiminin öğrenilmesi, bilim ve teknolojideki gelişmeler, radikal cerrahinin tek başına prognozu iyileştirmedeki yetersizliği meme kanseri tedavisinde cerrahiyle beraber farklı tedavi modellerinin geliştirilmesine ihtiyaç doğurmuştur. Meme kanserinin sistemik bir hastalık olduğu gerçeğinin anlaşılmasıyla birlikte en iyi sonuçlara multidisipliner yaklaşımla ulaşılacağı görülmüştür. Cerrahinin gün geçtikçe küçültülme çabası, tarama programları ile artan erken evre meme kanseri hastaları sayısı ile artık minimal invaziv tekniklerin konuşulduğu bugünlerde tedavi edilebilir tüm evrelerdeki hastalar için güncel kılavuzlardaki standart tedavi hala cerrahidir.

🔖

Cite This Article

Özdemir, M. (2026). Is Surgery Still the Main Treatment for Breast Cancer?. Atlas Journal of Medicine, Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı, 1–6. https://doi.org/10.54270/atljm.2026.119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (34)

  1. Smith E (2006) Edwin Smith Cerrahi Papirüsü: hiyeroglif çevirisi, çeviri ve yorumlama V1. Breasted JH (ed) Kessinger Yayıncılık: Montana
  2. Sakorafas GH. The origins of radical mastectomy. AORN J. 2008 Oct;88(4):605-8.
  3. Rissanen, P.M. Holsti, P. Vergleich zwischen konservatier und radikale chirurgie kombitiniert mit starlentherapic bein der behandlung des brustkrebses in stadium I Strahlentherapic 147:370, 1974.
  4. Anglem, T.J. And Camer, S.J. Cancer off breast. N. Eng. J. Med. 302:1258, 1980.
  5. Halsted WS. I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg. 1907 Jul;46(1):1-19. doi: 10.1097/00000658-190707000-00001. PMID: 17861990; PMCID: PMC1414357.
  6. Pierquin, B. Conservative treatment for carcinoma of the breast. Experience of Creteil-Ten years results. İn Harris JR. Hellman S. Silen W. (eds): Conservative management of breast cancer pp.11-14. Philadlephia JB. Lippincott, 1983.
  7. Turner L, Swindell R, Bell WG ve ark. Radical versus modified radical mastectomy for breast cancer. Ann R Coll Surg Engl. 1981 Jul;63(4):239-43. PMID: 7247286; PMCID: PMC2493789.
  8. Hirsch J. Radiumchirirgie des Brust Krebes Dtsch med Wochenschr. 53:1419-1421, 1927.
  9. Keynes G. The radium treatment of carcinoma of the breast. Br J Surg 1932; 19:415-80. 10.1002/bjs.1800197508
  10. Effects of Radiotherapy and Surgery in Early Breast Cancer — an Overview of the Randomized Trials. (1995). New England Journal of Medicine, 333(22), 1444–1456. doi:10.1056/nejm199511303332202
  11. Calle, R., Pilleron, J.P.: Conservative management of operable breast cancer. Ten years’ experience of the Foundation Curie. Cancer 42: 2045-2053, 1978.
  12. Sarrazin, D., Li, M.: Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 milimeters or less. Cancer 53: 1209-1213, 1984.
  13. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270-5. doi: 10.1038/bjc.1971.33. PMID: 5115829; PMCID: PMC2008453.
  14. Nolvadex Adjuvant Trial Organisation (NATO). Controlled trial of tamoxifen as adjuvant agent in the management of early breast cancer. Interim analysis at four years. Lancet. 1983; i:257–261
  15. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. New Engl. J. Med. 1988; 319:1681–1692.
  16. Powles T.J., Tillyer C.R. Jones A.L. ve ark. Prevention of breast cancer with tamoxifen — an update on the Royal Marsden Hospital pilot programme. Eur. J. Cancer. 1990; 26:680–684
  17. Slamon DJ, Leyland-Jones B, Shak S ve ark. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101. PMID: 11248153.
  18. Goodman LS, Wintrobe MM, Dameshek W et al. Nitrogen Mustard Therapy: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin’s Disease, Lymphosarcoma, Leukemia and Certain Related and Various Disorders. JAMA. 1984;251(17):2255–2261. Doi:10.1001/jama.1984.03340410063036
  19. Farber S, Diamond LK, Mercer RD ve ark. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948; 238:787–793. doi: 10.1056/NEJM194806032382301.
  20. Cooper RG. Combination chemotherapy in hormone-resistant breast cancer [abstract]. Proc Am Assoc Cancer Res 1969; 10: 15.
  21. O’Bryan RM, Luce JK, Talley RW ve ark. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973; 32: 1–8.
  22. Buzdar AU, Gutterman JU, Blumenschein GR ve ark. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 1978; 41: 1064–75.
  23. Nabholtz JM, Senn HJ, Bezwoda WR ve ark. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413–24.
  24. Giuliano AE, Kirgan DM, Guenther JM ve ark. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401. doi: 10.1097/00000658-199409000-00015. PMID: 8092905; PMCID: PMC1234400.
  25. Olson JA Jr, Fey J, Winawer J ve ark. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg. 2000 Dec;191(6):593-9. doi: 10.1016/s1072-7515(00)00732-8. PMID: 11129806.
  26. Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 2016; 264:413-420.
  27. Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla- Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 2017; 43:672-679.
  28. Sabel MS, Kaufman CS, Whitworth P ve ark. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol. 2004 May;11(5):542-9. doi: 10.1245/ASO.2004.08.003. PMID: 15123465.
  29. Simmons RM, Ballman KV, Cox C ve ark. ACOSOG investigators. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. Ann Surg Oncol. 2016 Aug;23(8):2438-45. doi: 10.1245/s10434-016-5275-3. Epub 2016 May 24. PMID: 27221361; PMCID: PMC5433250.
  30. Fine RE, Gilmore RC, Tomkovich KR ve ark. Cryoablation Without Excision for Early-Stage Breast Cancer: ICE3 Trial 5-Year Follow-Up on Ipsilateral Breast Tumor Recurrence. Ann Surg Oncol. 2024 Oct;31(11):7273-7283. Doi: 10.1245/s10434-024-16181-0. Epub 2024 Sep 16. PMID: 39283572; PMCID: PMC11452421.
  31. Charlotte E.C, David J.D, Kenneth E ve ark. SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial. Journal of Clinical Oncology 2023 41:16_suppl, TPS625-TPS625
  32. Shin Takayama, Masato Takahashi, Tomomi Fujisawa ve ark. Radiofrequency ablation without excision for breast cancer: 5-year results of ipsilateral breast tumor recurrence-free survival in the RAFAELO study (NCCH1409). Journal of Clinical Oncology 2024 42:16_suppl, 578-578
  33. Version 3.2025, 3/18/25 © 2025 National Comprehensive Cancer Network.
  34. Powles T.J., Tillyer C.R. Jones A.L. ve ark. Prevention of breast cancer with tamoxifen — an update on the Royal Marsden Hospital pilot programme. Eur. J. Cancer. 1990; 26:680–684